Apocrine sweat gland adenocarcinoma: A rare case report and review

Gatti, Arthur Paredes; Tonello, Luiza; Pfaffenzeller, William; Savóia, Fernando Oliveira; Goergen, Diego Inácio; Coan, Rodrigo De Pieri; Teixeira, Uirá Fernandes; Waechter, Fábio Luiz; Fontes, Paulo Roberto Ott

doi:10.1016/j.ijscr.2017.04.029

Cited by 10 publications

(13 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Apocrine carcinoma usually appears as a single, small nodule or a multinodular mass which is characterized by symptomatic progression. The incidence of Primary Apocrine Sweat Gland Carcinoma (PASGC) is quite low at 0.0049 to 0.0173 cases/100,000 persons per year [3,4]. These types of carcinomas comprises tumors with varied biological behavior.…”

Section: Discussionmentioning

confidence: 99%

Recurrent Malignant Apocrine Sweat Gland Carcinoma - A Case Report

Janga

Ziauddin

Patlolla

2021

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Apocrine carcinomas arise from normal or modified sweat glands. The slow-growing nature and rarity of sweat gland carcinomas complicate their diagnosis at the early stage. The incidence of PASGC is quite low at 0.0049–0.0173 cases/100,000 persons/year. A 21-year-old male patient was presented in February 2016 with small solitary mass in the right axilla with mild tenderness and pain. Underwent wide local excision and axillary dissection at our institution followed by adjuvant radio and chemotherapy. Later on, after 18 months developed local recurrence and was planned for re-surgery and a second phase of palliative radiotherapy. After a year, presented to the hospital with pin sized irregular swelling in the axilla. Sweat gland carcinomas which are rarely diagnosed create a pathological dilemma due to their unpredicted biological behavior. However, wide local excision with or without nodal dissection is the primary treatment till date. In this particular case even though patient had underwent axillary node dissection, patient had recurrence twice with no distant metastasis which is a key point to be noted. Thorough study of the available apocrine carcinoma case reports or case series, the better knowledge regarding the apocrine carcinoma can be obtained.

show abstract

Section: Discussionmentioning

confidence: 99%

Recurrent Malignant Apocrine Sweat Gland Carcinoma - A Case Report

Janga

Ziauddin

Patlolla

2021

Asian J Pharm Clin Res

View full text Add to dashboard Cite

show abstract

“…The standard treatment for PASGC is local excision with a clear margin of 1–2 cm along with ALND if clinically positive nodes are detected. It is considered that the most important predictor of survival may be lymph node metastasis (40–60%) [ 2 , 3 , 9 , 10 ]. Therefore, accurate diagnosis of lymph node metastasis is necessary.…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, accurate diagnosis of lymph node metastasis is necessary. The benefit of ALND for clinically node negative PASGC patients is unclear [ 1 , 10 ]. Previous studies have shown that SLNB was useful for those patients [ 6 , 7 , 11 ].…”

Section: Discussionmentioning

confidence: 99%

Sentinel lymph node biopsy of primary apocrine sweat gland carcinoma of the axilla: A case report and review of the literature

Sekine

Kawase

Yoshida

2020

International Journal of Surgery Case Reports

View full text Add to dashboard Cite

Highlights Primary apocrine sweat gland carcinoma (PASGC) is a rare subtype of sweat gland carcinoma, mostly occurring in the apocrine-dense regions. The role of sentinel lymph node biopsy (SLNB) for axillary PASGC treatment remains controversial because of its rarity. In axillary cases, to identify SLNs could be difficult because the lymphatic flow of the axillary skin is complicated, unlike the arm and areola. Although SLNB in sweat gland carcinoma has long been known and used, this is the first axillary PASGC case that was performed SLNB.

show abstract

“…The reported incidence of apocrine adenocarcinoma is approximately one in 6-20million patients per year [4]. The median patient age is 67 without racial or gender preference [4,5]. They are found in areas of high apocrine sweat gland density, mainly in the axilla and anogenital region, but also reported in the eyelid, scalp, nipple, lip, and others [4,5,[9][10][11][12].…”

Section: Case Discussionmentioning

confidence: 99%

“…The malignant counterpart is apocrine adenocarcinoma, a rare entity found in areas of high apocrine gland density, mainly in the axilla and anogenital region. However, there have been cases in the eyelid arising from Moll's glands, scalp, nipple, lip, and others [2][3][4][5]. Co-occurrence of apocrine adenocarcinoma and hidrocystoma is extremely rare and has only been reported in 5 cases [6].…”

Section: Introductionmentioning

confidence: 99%